

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIG. 1





FIG. 2



FIGS. 3A-3E




FIG. 4A




FIG. 4B

Treatment	# of mice with complete tumor eradication after therapy
L1C2 control + no treatment	0/8
L1C2 + intratumoral 10 ⁸ pfu Ad-CV	0/8
L1C2 + intratumoral 10 ⁸ pfu Ad-SLC	5/8

FIG. 5A
Table 1A

Groups	PGE2	VEGF	IFN-γ	GM-CSF	IL-10	IL-12	TGF-β	MG	IP-10
3LL + diluent	28.510 ± 400	757 ± 26	104 ± 15	244 ± 6	24 ± 6	5.820 ± 578	1.000 ± 200	15.100 ± 1.100	
3LL + SLC	8.737 ± 210*	222 ± 34*	549 ± 16*	56 ± 11	42 ± 13*	42 ± 1*	2.473 ± 26*	6.600 ± 100*	39.400 ± 2.300*

*p<0.01 compared with diluent-treated tumor-bearing mice. n = 6 mice/group.

FIG. 5B
Table 1B

Group	PGE-2	VEGF	IL-10	IFN-γ	GM-CSF	IL-12	MG	IP-10	TGF-β
Lung									
CC-10 + diluent	12419 ± 384	980 ± 38	213 ± 11	26 ± 5	74 ± 5	110 ± 8	47.8 ± 5	108 ± 6	281 ± 0
CC-10 + SLC	11945 ± 208	222 ± 53*	239 ± 20	4174 ± 26*	611 ± 11*	235 ± 15*	98.4 ± 4	187 ± 2*	154 ± 15*
FVB control	6023 ± 40	222 ± 53	129 ± 8	122 ± 28	73 ± 3	167 ± 7	72.3 ± 6	57 ± 5	118 ± 9
Splenocytes									
FVB control mice	72 ± 2	107 ± 36	85 ± 0	101 ± 24	44 ± 1	66 ± 8	89	96 ± 5	20 ± 2
Diluent-treated CC-10	643 ± 51	267 ± 14	87 ± 11	106 ± 3	45 ± 3	67 ± 6	42	63 ± 3	<15
SLC-treated CC-10	44 ± 10*	13 ± 1*	84 ± 11	107 ± 9	110 ± 4*	137 ± 5*	142*	216 ± 5*	17 ± 5
Lymph node									
FVB control mice	148 ± 3	204 ± 18	78 ± 6	98 ± 23	65 ± 2	195 ± 5	70	<15	102 ± 4
Diluent-treated CC-10	94 ± 3	142 ± 12	81 ± 4	89 ± 9	42 ± 2	95 ± 10	46	43 ± 3	139 ± 6
SLC-treated CC-10	113 ± 4	221 ± 32	86 ± 20	192 ± 8*	44 ± 3	233 ± 6*	106*	100 ± 2*	89 ± 7*

*p<0.01 compared to diluent-treated CC-10 tumor-bearing mice.

FIG. 6A
TABLE 2A

Groups	CD4			CD8			CD11c + DEC205		
	IFN-γ	%	MCF	GM-CSF	%	MCF	IFN-γ	%	MCF
Tumor									
3LL	3.6	193	4.8	31	1.9	389	1.7	44	4
3LL + SLC	7.4*	187	5.3	52*	3.2*	306	2.7*	47	13*
LN									
3LL	0.9	86	0.8	50	0.9	131	0.5	78	32
3LL + SLC	1.7*	340*	1.2*	181*	1.7*	181	1.3*	107*	40*

* $p < 0.01$ ($n = 6$ mice/group)

FIG. 6B
TABLE 2B

Groups	CD4 [*]				CD8 [*]				CD11c+DEC205			
	IFN- γ		GM-CSF		IFN- γ		GM-CSF		IFN- γ		GM-CSF	
	%	MCF	%	MCF	%	MCF	%	MCF	%	MCF	%	MCF
Tumor												
CC-10 + diluent	2	124	2.4	38	2	307	1.5	53	3.2	121		
CC-10 + SLC	5 ^a	187	5.2 ^a	89	5.3 ^a	311	3.7	89	11.7 ^a	132		
Lymph node												
CC-10 + diluent	3.2	154	3.3	80	1	200	1.3	52	5.3	54.4		
CC-10 + SLC	6.8 ^a	173	5.7 ^a	102	6.8 ^a	244.9 ^a	3 ^a	55	12.7 ^a	79		
Spleen												
CC-10 + diluent	3.9	163	1.5	60	1.1	311	0.7	88	5.9	82		
CC-10 + SLC	4.7	206 ^a	1.6	168 ^a	3.8 ^a	352	2.1 ^a	54	11.4 ^a	101		

^a $P < 0.01$, $n =$ six mice/group. For DC staining, MCF (mean channel fluorescence) is noted for DEC205. Experiments were repeated twice.

FIG. 7A
TABLE 3A

Group	IFN- γ	GM-CSF	IL-10	IL-12
Splenocytes				
Mice without tumor, constitutive	220 \pm 30	0	0	78 \pm 1
Stimulated with 3LL	85 \pm 19	37 \pm 2	0	16 \pm 3
Diluent-treated, constitutive	117 \pm 41	0	18 \pm 1	60 \pm 12
Stimulated with 3LL	97 \pm 13	23 \pm 9*	1566 \pm 93	51 \pm 1
SLC-treated, constitutive	113 \pm 21	0	16 \pm 1	111 \pm 1
Stimulated with 3LL	2731 \pm 99*	71 \pm 2*	181 \pm 14*	206 \pm 7*
Lymph node				
Mice without tumor, constitutive	248 \pm 1	16 \pm 1	0	60 \pm 1
Stimulated with 3LL	87 \pm 12	34 \pm 7	0	48 \pm 1
Diluent-treated, constitutive	166 \pm 16	16 \pm 1	297 \pm 10	25 \pm 1
Stimulated with 3LL	96 \pm 17	52 \pm 8	816 \pm 25	84 \pm 6
SLC-treated, constitutive	256 \pm 10	19 \pm 1	0	25 \pm 1
Stimulated with 3LL	1242 \pm 270*	49 \pm 6	133 \pm 17*	108 \pm 3*

* $p<0.01$ compared with diluent-treated mice and SLC constitutive levels: $n=6$ mice/group.

FIG. 7B
TABLE 3B

Group	IFN- γ	GM-CSF	IL-10
No tumor			
Mice without tumor, constitutive	634 \pm 45	55 \pm 7	32 \pm 4
Stimulated with CC-10 cells	685 \pm 39	87 \pm 5	147 \pm 8
Diluent-treated			
Diluent-treated, constitutive	400 \pm 38	104 \pm 11	78 \pm 2
Stimulated with CC-10 cells	379 \pm 28	132 \pm 5	1000 \pm 69
SLC-treated			
SLC-treated, constitutive	617 \pm 42	185 \pm 3	49 \pm 2
Stimulated with CC-10 cells	2265 \pm 107 ^a	287 \pm 10 ^a	200 \pm 7 ^a